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ABSTRACT 
Background: Within Parkinson’s there is a spectrum of clinical features at presentation 
which may represent sub-types of the disease.  However there is no widely accepted 
consensus of how best to group patients. 
Objective: Use a data-driven approach to unravel any heterogeneity in the Parkinson’s 
phenotype in a well-characterised, population-based incidence cohort.  
Methods: 769 consecutive patients, with mean disease duration of 1.3 years, were assessed 
using a broad range of motor, cognitive and non-motor metrics. Multiple imputation was 
carried out using the chained equations approach to deal with missing data.  We used an 
exploratory and then a confirmatory factor analysis to determine suitable domains to include 
within our cluster analysis. K-means cluster analysis of the factor scores and all the variables 
not loading into a factor was used to determine phenotypic subgroups. 
Results: Our factor analysis found three important factors that were characterised by: 
psychological well-being features; non-tremor motor features, such as posture and rigidity; 
and cognitive features.   Our subsequent five cluster model identified groups characterised by 
(1) mild motor and non-motor disease (25.4%), (2) poor posture and cognition (23.3%), (3) 
severe tremor (20.8%), (4) poor psychological well-being, RBD and sleep (18.9%), and (5) 
severe motor and non-motor disease with poor psychological well-being (11.7%). 
Conclusion: Our approach identified several Parkinson’s phenotypic sub-groups driven by 
largely dopaminergic-resistant features (RBD, impaired cognition and posture, poor 
psychological well-being) that, in addition to dopaminergic-responsive motor features may be 
important for studying the aetiology, progression, and medication response of early 
Parkinson’s. 
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INTRODUCTION  
Parkinson’s Disease (PD) is a common neurodegenerative condition encompassing both 
motor and non-motor symptoms.  Even within pathologically defined patient cohorts, there 
remains a spectrum of clinical features, treatment response and prognosis.[1] These 
differences in clinical phenotype may represent different PD subtypes, but there is no widely 
accepted consensus on the criteria for such groups.  Clinically accurate sub-typing may result 
in improved delineation of aetiological mechanisms, better prognostic counselling, and 
improved targeting of disease modifying therapies.  
Attempts to sub-classify PD include “top-down” approaches which depend on an a priori 
assumption, such as the division of subjects by motor phenotype and age of onset.[2, 3] 
Unfortunately, this approach relies on accurate clinical observation to recognise patterns from 
all available variables, which is difficult given the breadth of clinical features. Recently, 
attempts at subtyping have employed data-driven, “bottom-up” approaches, allowing 
unexpected patterns or discriminating features to be determined.[4] Outcomes of the group 
characteristics depend heavily on the breadth and depth of the variables inputted into the 
models. In this study, we have used an approach with key methodological refinements 
including: 1) restriction to incident patients, to avoid the confounding effects of disease 
duration, with a far broader range of motor and non-motor assessments than most previously 
published studies 2) using factor analysis methods to reduce the large number of motor/non-
motor variables into a smaller number of clinically important domains describing patient 
variability 3) using k-means cluster analysis with the inclusion of additional clinical features 
that may have not been already captured by the factor analysis.  
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MATERIALS AND METHODS 
Patient selection with inclusion/exclusion criteria 
PD patients diagnosed within the past 3.5 years were prospectively recruited as part of the 
Oxford Parkinson’s Disease Centre (OPDC) cohort study from 11 hospitals across the 
Thames Valley covering a population of approximately 2.1 million (PD-Discovery, website: 
http://opdc.medsci.ox.ac.uk). Full details of this cohort are described elsewhere,[5] with 
participants being recruited between September 2010 and September 2014.  
Patients were eligible for study inclusion if they met the UK Parkinson’s Disease Society 
Brain Bank (UKPDBB) criteria for the diagnosis of idiopathic PD, as judged by a 
neurologist, with no atypical features to suggest an alternative diagnosis following systematic 
clinic assessment derived from the NIH PD-DOC study questionnaire 
(http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-11-001.html).  Patients with secondary 
parkinsonism due to head trauma or medication use, or features of atypical parkinsonism 
syndromes, such as multiple system atrophy, progressive supra nuclear palsy, corticobasal 
degeneration, dementia with Lewy bodies, or with significant documented postural BP drop 
on standardised measurement or significant urinary symptoms were excluded.  Each patient 
was assigned a percentage probability that they met UKPDBB criteria for PD diagnosis by 
the research neurologist following the study visit. Date of symptom onset was recorded as the 
date the patient or their carer first became aware of motoric symptoms in relation to their PD, 
even if occurring on a mild or intermittent basis without initial obvious progression; for 
example hand tremor, reduced manual dexterity or arm swing. Date of diagnosis was 
recorded as the date the patient was first given a diagnosis of PD by their hospital specialist 
(neurologist or geratologist), with the subsequent delay from motoric symptom onset to 
diagnosis, and delay from date of diagnosis to first (baseline) research clinic visit calculated. 
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Disease duration from motoric symptom onset to date of first (baseline) research clinic visit 
was also calculated. 
Patient evaluation 
A full description of the tests and assessments used to assess the Discovery cohort has been 
published.[5, 6] Assessments were done by the patient completing self-evaluating 
questionnaires at home and a clinic consultation conducted by a trained neurologist and a 
nurse.  Where patients were taking dopaminergic medications, the assessment was carried out 
in the clinically-defined on-state. Medication use was recorded allowing the calculation of the 
levodopa equivalent daily dose (LEDD).[7]  Patient response to antiparkinson therapy was 
assessed using the physician-rated Clinical Global Impression of Change Scale (CGI-C) [8].  
Included in the cluster analysis were:  the Movement Disorders Society (MDS) revised 
Unified Parkinson’s Disease Rating Scale (UPDRS part I and part III ); ‘Sniffin’ Sticks 16-
item odour identification test; Big Five Inventory – extraversion scale; Epworth Sleepiness 
Scale; REM Sleep Behaviour Disorder Screening Questionnaire; Leeds Anxiety and 
Depression Scale (LADS); Becks Depression Inventory (BDI); Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease; Honolulu Asia Aging Study Constipation 
Questionnaire; Montreal Cognitive Assessment; Phonemic and Semantic verbal fluency; 
Purdue Peg-board Test; the timed Get Up and Go test; Flamingo test; Orthostatic blood 
pressure measurement. We explicitly did not include age at onset as this is a demographic 
variable rather than a feature of PD. Age at onset could influence the phenomenology of PD 
through two mechanisms: (a) it may confound phenotypic variability due to age-related 
comorbidity so older patients will have worse motor function unrelated to their PD and/or (b) 
it may be a proxy marker for different pathophysiological mechanisms which in turn alter the 
presenting features of PD. Adjusting for age would be helpful for the former but harmful for 
the latter as it would reduce the likelihood of identifying different sub-groups.  Given the 
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exploratory nature of the analysis, we therefore chose to see how any sub-types related to age 
in our analyses. 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study was undertaken with the understanding and written informed consent of each 
subject, with the approval of the local NHS ethics committee, and in compliance with 
national legislation and the Declaration of Helsinki. 
Analysis dataset 
Analysis was restricted to patients who were diagnosed within the previous 3.5 years and had 
a high probability of idiopathic PD (≥ 90% clinician-determined) following careful, 
structured neurological assessment.  Where available, we used the latest follow-up visit to 
determine the likelihood of PD (n=538, 58.2% seen after 18 and n=170, 18.4% seen after 36 
months).   
Dealing with missing data 
Where questionnaire data were partially completed we used the mean score if 80% or more 
questions were answered within a questionnaire.  We then carried out multiple imputation 
using the chained equation approach to create 10 imputed datasets.   
Determining variables to include within the cluster analysis 
Our first step was to carry out an exploratory factor analysis (EFA) within each imputed 
dataset.  We determined the number of important factors, only retaining those with an 
eigenvalue > 1.  A promax (oblique) rotation was used and only variables with a loading 
modulus of ≥ 0.4 were deemed sufficiently important to carry over to the second step.  
The second step involved a confirmatory factor analysis (CFA) using the multiply imputed 
data given the results from the EFA and examining the following goodness of fit statistics:  
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Comparative Fit Index (CFI), Tucker-Lewis Index (TLI) and the Root Mean Square Error of 
Approximation (RMSEA).  A model was considered to fit the data well if CFI was ≥ 0.90, 
TLI ≥ 0.90 and RMSEA ≤ 0.06.[9] We estimated factor scores for each individual from our 
CFA within each imputed dataset.  At this stage we also considered other clinically important 
variables for the cluster analysis that were not found to load in any of our factors.   Factor 
scores and other clinically important variables were combined using Rubin’s rules[10] to 
construct a single dataset for carrying out the cluster analysis. 
Cluster analysis 
We then examined if any variables which did not load on the factor analysis had value in 
identifying sub-groups by standardising them, so that they had equal weighting within the k-
means cluster analysis and testing their inclusion in the cluster analysis.  Ordered categorical 
and binary variables were weighted using the rules set out by Hennig et al [11]. To determine 
the optimum number of clusters we carried out hierarchical clustering using the Ward 
algorithm[12] calculating the Calinski/Harabasz pseudo-F index[13] and the Duda/Hart 
pseudo-T-squared.[14] A higher value of Calinski/Harabasz pseudo-F index and a smaller 
value of the Duda/Hart pseudo-T squared indicate more distinct clustering. We considered 
models with between 2 to 5 clusters.   
We then carried out k-means cluster analysis using the optimum number of clusters 
determined from the hierarchical analysis. To ensure convergence to the global maximum, we  
fitted the model using 500 random starts, and estimated the Calinski/Harabasz pseudo-F 
index stopping rule[13] to determine the optimal solution. 
To test the utility of the sub-group classification, we examined the associations between the 
clusters with variables not included within the factor/cluster analysis, such as age at onset, 
time since diagnosis, and time since symptom onset, response to medication using the CGI-C, 
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LEDD and the number of untreated individuals.  We also examined the association between 
cluster membership and classification of PD patients into tremor dominant or postural 
instability/gait difficulty (PIGD), popularised by Jankovic [2] and updated by Stebbins et 
al,[15] for the MDS UPDRS.   
To further test the reliability of the cluster solutions we applied a cross-validation approach 
where the data was randomly split into halves five times and the k-means cluster analysis 
repeated separately on each half.  The number of individuals classified into the correct cluster 
was then determined.  Hair et al. suggest that a very stable cluster solution would lead to 
>90% being correctly classified, a stable cluster solution 80-90% being correctly classified 
and a somewhat stable cluster solution 75-80% being correctly classified [12]. 
Computing 
STATA version 13 was used to carry out the multiple imputation, Exploratory Factor 
Analysis (EFA) and the k-means cluster analysis.  The Confirmatory Factor Analysis (CFA) 
and estimation of factor scores was carried out within Mplus. 
RESULTS 
At the time of this analysis, OPDC had recruited 924 patients (see Figure 1) but we excluded 
154 subjects either because of disease duration (41), they had a prior PD probability of <90% 
clinically (112), or because of a concomitant neurological disorder leading to significant 
disability in addition to PD, such that assessment of motor function was invalid (1).  One 
individual was subsequently found to be a duplicate and was dropped from the cluster 
analysis.  This left 769 subjects (age of onset 64.8 years) for the analysis. The baseline 
characteristics are presented in Table 1. 12.7% of patients were untreated and the mean MDS-
UPDRS part III was 26.3. The variables included in our factor analysis had between 0.3%-
7.8% missing values.  
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Exploratory factor analysis (EFA) 
We included 34 variables measuring motor and non-motor domains within our EFA. MDS-
UPDRS part III was split into four domains (rigidity, bradykinesia, postural, and tremor) to 
enable better discrimination.  We also included the part III question related to speech.  
Laterality of symptoms was derived from the difference in responses between corresponding 
questions related to the right- and left-side from the MDS UPDRS part III (see Web Table 1 
for more detail on how each variable was derived). 
Within each imputed dataset we found four factors to have an eigenvalue greater than 1. The 
first factor was a mixture of variables measuring non-motor features mostly related to 
psychological well-being: LADS, BDI, QUIP, BFI neuroticism and apathy, fatigue and pain 
domains from MDS-UPDRS. The second factor captured motor features either from the MDS 
UPDRS (rigidity, bradykinesia, postural, speech) or quantified motor performance (‘Get up 
and Go’ test, the flamingo test and Purdue pegboard test).   The third factor captured 
cognition (MOCA, MMSE and phenomic and semantic fluency). A fourth factor captured 
constipation (from the UPDRS part I constipation question and Honolulu Asia Aging Study 
constipation questionnaire).   
Confirmatory factor analysis (CFA) 
Our EFA found very consistent results between the imputed datasets. For the CFA we could 
not estimate a constipation factor since a factor with only two variables is not identifiable. 
Our CFA of the remaining three factors fell slightly short of our pre-defined goodness of fit 
criteria with a CFI of 0.79, TLI of 0.88, and a RMSEA of 0.082.  It is likely that our poor 
goodness of fit is due to the large number of variables in the first two factors [16] and our 
sample size [12].  However since we are only interested in calculating factor scores and not 
testing the validity of our structural model we kept the CFA as defined.  We named factor 1, 
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“psychological well-being”, factor 2, “non-tremor motor” and factor 3, “cognitive” (Table 2). 
Within each factor, variable loadings varied from 0.35 to 0.85, 0.43 to 0.76, and 0.59 to 0.78 
respectively. 
The factor analysis did not capture a number of clinical features probably since they were not 
significantly correlated with any of the other variables in the analysis.  Hence we decided to 
include any variable in our cluster analysis that was not loading into one of our factors.  We 
did however exclude the other four BFI variables (since no other previous cluster analysis has 
looked at these personality traits) and the UPDRS constipation variable (since the other 
constipation variable was measuring the same trait) for the sake of parsimony. 
Hierarchical and K-means cluster analysis 
Web Table 2 shows the statistics used to determine the optimum number of clusters from the 
hierarchical cluster analysis fitted using the Ward algorithm.  Different conclusions on the 
optimum number of clusters would be drawn from different statistics.  The Calinski/Harabasz 
pseudo-F index favoured a two cluster solution, and the Duda/Hart pseudo-T-squared a five 
cluster solution.  This highlights the need for substantial researcher judgement on 
determining the optimum number of clusters and also the exploratory nature of cluster 
analysis. Because the two cluster solution appeared to discriminate patients mainly on disease 
severity with a poor and good group (Web Figure 1), we chose to go forward with the 
exploratory five cluster solution as more helpful in describing the clinical heterogeneity 
between patients.  Figure 2 shows the means values of each of the standardised variables 
within each cluster, all variables were coded such that positive indicates worse and negative 
better than average score.  For the laterality variable positive is more bilateral than average 
and negative more unilateral than average.  The groups were ordered in terms of size with the 
largest as the first. Table 3 shows the association between the clusters and ten variables not 
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included within the factor analysis. There was moderate evidence of a difference in the mean 
duration of disease between clusters however in absolute terms the difference was negligible 
and hence we are confident these clusters are not an artefact of disease duration. 
Patients in group 1 (25.4%) showed a milder form of PD and they also had a lower than 
average age at onset, a higher proportion of females, more drug naïve individuals and a lower 
LEDD.   The second group (23.3%) comprised of individuals with worse than average non-
tremor motor symptoms, cognitive features, smell, postural hypotension and with bilateral 
disease.  They also had a higher than average age at onset and a lower proportion of females.  
Within this cluster over 49% were classified as PIGD, which was larger than the average 
proportion (34%). This cluster had higher than average LEDD and a higher proportion who 
responded well to therapy. The third group (20.8%) had patients with worse than average 
tremor scores but who were better than average in most of the other domains and with very 
unilateral disease.  These individuals had similar average age at onset to the overall 
population and 84% of this cluster was classified as tremor dominant compared to 54% in the 
entire study population. This cluster had larger proportion of untreated individuals than the 
study population (18% versus 13%), and a lower than average LEDD.  This cluster also had a 
lower proportion who responded well to PD therapy. The fourth group (18.9%) were marked 
by poor psychological well-being, RBD, and sleep problems.  They also seemed to have 
better motor function, cognitive and postural hypotension than average with a lower than 
average age at onset, responded well to medication and were also on a higher than average 
LEDD.   The fifth and smallest group (11.7%) were worse than average on almost all of the 
domains (except smell), showing a more severe form of PD.  This group showed very severe 
psychological well-being which could be a secondary response to their fast progression or 
part of the clinical endophenotype.  Within this cluster about 48% were classified as PIGD, 
very few individuals were untreated and they had a higher than average LEDD.  The 
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equivalent analysis for the two cluster solution is shown in web-table 3 for comparison.  Web 
figure 2 shows the association between the UPDRS phenotype and the 5 cluster solution.  It is 
interesting that although the third cluster is almost completely tremor dominant this cluster 
only includes about 32% of all the tremor dominant individuals.  This highlights the 
differences in these approaches, that tremor dominant individuals have relatively more tremor 
problems compared to PIGD problems but do not necessarily have worse than average 
tremor. 
Please note that the binary variable, hallucinations, and the categorical variables, urinary and 
constipation, have been scaled in a way so that they have equal weighting in the k-means 
cluster analysis when compared to the more continuous variables.  However this does not 
mean that the distance of the within cluster means from the population average for these three 
variables can be interpreted in the same way as the other variables.  Instead they should be 
considered relative to the other clusters.  For instance the severity of urinary symptoms in the 
fifth cluster is worse that the severity in the fourth cluster.  However we cannot be certain 
whether the severity of urinary symptoms in the fifth cluster is any less than the severity of 
sleepiness problems in the fifth cluster even though the within cluster mean of sleepiness is 
further from the population average. 
Web Table 4 shows the stability of the five cluster solution using our cross-validation 
approach.  On average 73.8% of individuals were correctly classified which is close to the 
borders of a somewhat stable solution according to the Hair et al. criteria. The stability across 
the five split datasets was not consistent ranging from stable (83.7% correctly classified) to 
an unstable solution (64.5% correctly classified) so without an external validation it is 
difficult to determine the stability of our five cluster model.   However the stability of the two 
cluster solution in the cross-validation is much better with on average 95.9% of individuals 
being correctly classified (web table 5), a very stable solution which was consistent across the 
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five split datasets.  The apparent stability of the 2 cluster solution compared to the 5 cluster 
solution is not particularly surprising since there are 1 compared to 4 ways of incorrectly 
classifying an individual in the two and five cluster solutions respectively. 
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DISCUSSION 
Our analyses suggest that there may be five sub-groups of patients with recently diagnosed 
PD:  1) mild motor and non-motor disease, 2) poor posture, gait, cognition, smell and 
postural hypotension, 3) severe tremor, 4) poor psychological well-being, RBD and sleep, 
and 5) severe motor, non-motor and cognitive disease, with poor psychological well-being. 
Our initial approach used a bottom-up data-driven approach to group together individuals 
with similar symptoms with little a priori assumptions. However, one limitation of using a 
purely data-driven approach is that the choice of variables and their breadth will partially 
determine what factors are identified i.e. a badly measured domain, even though clinically 
important, will appear statistically less informative than another for which several scales have 
been included. We therefore felt it important to supplement the factor analysis with a second 
stage approach where we added nine other domains that had not emerged from the factor 
analysis. This combined approach has advantages over simply using a priori assumptions 
about the importance of UPDRS tremor and non-tremor sub-items in defining such 
phenotypes.[2] 
Depending on which statistical approach we chose, we could have decided that the two 
cluster solution was more appropriate.  However this solution only seemed to group people 
essentially as good or bad across a range of disease severity measures (motor, non-motor, 
psychological well-being and cognition- see Web Figure 1).  The five cluster solution 
allowed for disease severity measures to be preferentially affected, for example group 3) 
above who score poorly on tremor motor measures with relative sparing of non-tremor motor, 
cognitive and psychological well-being measures. This may be a more valid representation of 
the PD disease spectrum encountered in routine clinical practice. Interestingly, the five 
cluster solution might be more clinically relevant as the two cluster solution found no 
evidence of an association with drug responsiveness, (p=0.13, see web table 3) whilst the five 
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cluster solution did find strong evidence of an association between cluster grouping and 
levodopa response (p=0.0004).   
One caveat for this study is that levodopa responsiveness was assessed using the clinician-
rated Clinical Global Impression of Change Scale (CGI-C). This retrospective questionnaire 
involves the clinician asking the patient (and carer) about their overall impression of motor 
response to previously trialled dopaminergic medications. The CGI-C therefore, is likely to 
be a less accurate measure of true levodopa response when compared to formal levodopa 
challenge testing for example. While we have performed this in a patient subgroup, 
unfortunately overall numbers are small due to practical purposes, and insufficient to extend 
to the more general cluster model being presented here. Caveats aside, it is interesting to note 
that cluster 2 (which resembles PIGD with impaired postural and cognitive function) has a 
good CGI-C medication response similar to cluster 4, despite these subjects being older. One 
of the difficulties in interpreting these results is that this group also have the fewest number 
of drug naïve patients, possibly because their parkinsonian motor features are more severe 
and disabling than those with tremor-dominant disease. Hence this may be biasing the 
proportions in the CGI-C results if we assume that drug naïve would show excellent response 
had they been treated. In addition this may also reflect a “ceiling effect” whereby milder 
tremor-dominant patients despite showing drug responsiveness can only improve to a more 
moderate degree than those with more severe disease. Lastly, cluster 2 has a higher LEDD so 
may have had the opportunity to demonstrate a bigger drug response compared to other 
clusters. The higher LEDD may also reflect the more severe motoric symptoms 
(bradykinesia, rigidity, and gait imbalance) experienced by this group, which are likely to be 
stronger determinants of disability than tremor symptoms, hence driving up the increased 
overall treatment doses. Future work will focus on comparing the accuracy of GCI-C versus 
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formal levodopa challenge in assessing medication response and predicting progression in 
early PD. 
At least two phenotypes defined in the current study, namely 4) poor psychological well-
being, RBD and sleep and 5) severe motor, non-motor and cognitive disease with poor 
psychological well-being, would have been missed using conventional “top-down” PD 
classification models. These findings are novel and potentially of high clinical relevance, as 
they underline the importance of early non-motor symptoms such as RBD, anxiety, 
depression, apathy, pain and fatigue in underpinning the disease heterogeneity seen in early 
PD. To date, few studies using data-driven techniques have assessed the baseline importance 
of non-motor symptoms in such a large well-characterised incident PD cohort. This is 
particularly relevant given the increasingly acknowledged importance of non-motor 
symptoms over and above motor symptoms in determining patient-related quality of life and 
subsequent decline.[17]  Symptoms such as RBD, which can manifest prior to the onset of 
motoric symptoms, are characterised pathologically by involvement of the locus coeruleus, 
subcoeruleus, pedunculopontine and serotonergic raphe nuclei.[18]  
The co-existence in group 5 of significantly worse scores in both motor and non-motor 
domains highlights the importance of the latter, and in particular psychological well-being 
which may or may not be secondary to a worse clinical evolution. This group had poor scores 
across both subjective and objective evaluations of motor, cognitive and other non-motor 
domains, thus excluding the possibility that they simply reflect a poor perception of personal 
well-being, which is a common occurrence in mood disorders such as anxiety and depression. 
Although every effort was made to exclude atypical Parkinsonism from our analysis, it is of 
course possible that a proportion of subjects in group 5 do not have PD but rather an atypical 
parkinsonian disorder such as multiple system atrophy or progressive supranuclear palsy. As 
we follow-up our subjects over the next 10 years, we will be able to determine if atypical 
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features emerge in this subgroup and ultimately post-mortem pathological diagnosis should 
help clarify if they have a more rapidly progressive form of PD or atypical Parkinsonism. 
Patients in group 4 scored particularly poorly on RBD measures, however function on motor 
and cognitive testing was good compared to other groups. This, together with the fact that 
RBD is a prodromal feature, which may have a 15-year latency before the emergence of 
motor symptoms,[19] might suggest that RBD is a risk but not a prognostic marker for 
subsequent PD.  Previous longitudinal studies have also shown that concomitant RBD was 
not associated with greater worsening of motor disability scores, cognition or depression, in 
patients with PD.[20-22]  
It is uncertain whether the phenotypic features of group 2, who are on average much older, 
merely reflect age-related co-morbidities such as poor posture, cognition, smell, postural 
hypotension, or are a distinct aetiological sub-group. 
A recent study using principle component analysis[23] in a prevalent PD cohort found that a 
composite score of predominantly nondopaminergic (PND) features which are largely 
insensitive to dopaminergic medication (postural instability, gait difficulty, cognitive 
impairment, depressive symptoms, psychotic symptoms, excessive daytime somnolence and 
autonomic dysfunction) might provide a more accurate evaluation of disease severity and 
progression in PD. Our results support this finding and raise the important issue of how best 
to select patients for future disease-modifying or neuroprotective trials in PD.  
If only certain sub-groups respond to a neuroprotective agent, existing trials are more likely 
to result in a false negative result and future trials will need far larger sample sizes to group 
according to baseline phenotype with concomitant cost implications. It is unclear as to 
whether the 12% of PD patients assigned to group 5, who appear severe across a range of 
motor and non-motor measures, should be selected as being the most likely to benefit from 
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future disease modifying interventions, or might be least likely to benefit due to more 
advanced pathophysiology.  Phenotypic differences seen across PD might therefore be a 
major contributing factor to the current lack of a convincing neuroprotective agent for this 
disease, despite multiple drug trials in this field. 
Our results are consistent with several studies applying cluster methodology in PD[24-33] 
that found a milder disease group with a young age at onset,[25, 26, 28-33] a group with 
severe gait dysfunction and cognitive impairment,[24, 27] and a tremor dominant group.[28, 
29, 31] Most studies have found a rapid disease progression group with an older age at 
onset.[25-32] The relationship between cognitive function and impairments in gait, posture 
and non-tremor motor features in PD has been well documented in previous studies.[34] It 
seems that our finding of a group which has poor RBD, psychological well-being and 
sleepiness has not been found in previous studies, possibly because information about these 
features have not always been collected.  
These sub-groups have been derived from baseline visits, hence are not confounded by 
disease duration.  Future evaluation will determine whether patients retain their initial clinical 
phenotype or whether changing from one clinical phenotype to another is an important 
marker of subsequent progression. We are currently undertaking an independent replication 
in collaboration with a second UK cohort (Tracking Parkinson’s Disease) which used a very 
similar methodology (90% of variables are the same).  
We cannot yet draw firm conclusions as to the prognostic value of these clusters, but with 
further follow-up we will determine whether this classification is of greater value than 
existing approaches which discriminate patients based on simpler baseline measures.  We 
will also test whether these clusters have biological or clinical utility by comparing data on 
genotypes, biomarkers, including neuroimaging as well as responsiveness to drug therapy, 
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and the onset of clinically-meaningful end points, such as motor fluctuations, dyskinesias, 
dementia, dependency or institutionalisation and long-term mortality. 
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TABLES 
Table 1.  Basic baseline descriptives of patients 
Variable Observed 
N 
Mean (sd; range) or n (%) 
Female  769 261 (33.9%) 
Ethnicity (non-white) 764 11 (1.4%) 
Age onset (years)  765 64.77 (9.74; 28.17 - 87.45) 
Disease duration from onset (years)  765 2.92 (1.86; 0.16 - 13.90) 
Disease duration from diagnosis (years)  765 1.32 (0.96; 0.01 - 3.50) 
Delay from first motoric symptom onset 
to diagnosis (years) 
762 1.61 (1.64; 0 – 13.5) 
MDS-UPDRS part Ia 759 8.62 (5.16; 0 - 33) 
MDS-UPDRS part IIa 763 8.67 (6.13; 0 - 35) 
MDS-UPDRS part IIIa 768 26.33 (11.00; 5 - 77) 
MDS-UPDRS part IVa 767 0.26 (0.97; 0 - 11) 
MDS-UPDRS total (parts I + II + III + 
IV) a 
758 43.87 (17.85; 7 - 123) 
MOCA (adjusted for education years) a 764 24.98 (3.36; 13 - 30) 
Untreated 766 97 (12.7%) 
Levodopa equivalent daily dose  762 284.38 (212.83; 0 - 1267.5) 
Hoehn and Yahr: median (IQRb) ; mean 
(range) 
768 2 (2-2) ; 1.84 (1-3) 
aChanged denominator where 80% or more of questions were answered 
bInter-quartile range 
Motor assessments (UPDRS and Hoehn and Yahr) were rated in the clinically-defined ‘on 
medication’ state for treated PD patients. 
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Table 2. Confirmatory factor analysis standardised factor loadings of variables selected from 
exploratory factor analysis.   
Variable Factor 1 
psychological  
well-being 
Factor 2 
Non-tremor 
motor 
Factor 3 
cognitive 
 
UPDRS apathy 0.581   
UPDRS fatigue 0.675   
UPDRS pain 0.589   
BFI – neuroticism 0.529   
Leeds anxiety 0.718   
Leeds depression 0.756   
BDI 0.850   
QUIP 0.353   
UPDRS speech  0.452  
UPDRS rigidity  0.429  
UPDRS bradykinesia  0.560  
UPDRS postural  0.721  
Purdue peg board  -0.662  
Purdue assembly task  -0.656  
Get go  0.757  
Flamingo  0.600  
MOCA    0.778 
MMSE   0.593 
Phenomic fluency   0.622 
Semantic fluency   0.727 
CFI = 0.786    
TLI = 0.875    
RMSEA = 0.082    
CFI = Comparative Fit Index, TLI = Tucker-Lewis Index, and RMSEA = Root Mean Square 
Error of Approximation.  CFI, TLI and RMSEA are all measures of model fit 
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Table 3. Association of clusters with variables not included within the cluster analysis, along 
with a p-value derived from a hypothesis test that the variable is equally distributed (i.e. same 
mean or same proportion) amongst the five clusters.  Note that these variables were derived 
from the complete case and there was some missingness associated with these variables 
Variable 
(Hypothesis test 
statistic; p-
value) 
Total 
(N=769) 
Cluster 1 
(N=195, 
25.4%) 
Cluster 2 
(N=179, 
23.3%) 
Cluster 3 
(N=160, 
20.8%) 
Cluster 4 
(N=145, 
18.9%) 
 Cluster 5 
(N=90, 
11.7%) 
Female a 
( 12.1; p=0.0166) 
261 
(33.9%) 82 (42.1%) 45 (25.1%) 56 (35.0%) 49 (33.8%) 29 (32.2%) 
Disease duration 
from onsetb 
( 2.5; p=0.0423) 2.9 (1.9) 2.7 (1.6) 2.8 (1.7) 3.0 (1.9) 3.1 (2.0) 3.3 (2.2) 
Disease duration 
from diagnosisb 
( 3.7; p=0.0052) 1.3 (1.0) 1.1 (0.9) 1.4 (1.0) 1.3 (1.0) 1.5 (1.0) 1.4 (0.9) 
Age onsetb  
( 30.0; p<0.0001) 
64.8 
(9.7) 61.8 (8.7) 70.4 (7.7) 64.2 (9.7) 61.0 (9.3) 67.1 (10.8) 
Age onset <50 a  
( 18.6; p=0.0009) 
60 
(7.8%) 20 (10.3%) 3 (1.7%) 16 (10.0%) 18 (12.5%) 3 (3.4%) 
UPDRS motor phenotype a 
( 104; p<0.0001) 
   Tremor       
dominant 
407 
(53.8%) 
118 
(61.5%) 65 (37.1%) 
132 
(83.5%) 58 (40.6%) 34 (38.6%) 
Indeterminate 95 
(12.6%) 22 (11.5%) 24 (13.7%) 12 (7.6%) 25 (17.5%) 12 (13.6%) 
   Postural 
instability gait 
difficulty 
254 
(33.6%) 52 (27.1%) 86 (49.1%) 14 (8.9%) 60 (42.0%) 42 (47.7%) 
Clinician global impression of change (CGI-C)  a 
( 35.4; p=0.0004) 
Much or very 
much improved 
354 
(48.7%) 83 (46.1%) 96 (55.5%) 59 (39.6%) 77 (55.8%) 39 (44.8%) 
Minimally 
improved 
188 
(25.9%) 49 (27.2%) 42 (24.3%) 34 (22.8%) 34 (24.6%) 29 (33.3%) 
No change to 
much worse 
124 
(17.1%) 25 (13.9%) 29 (16.8%) 34 (22.8%) 19 (13.8%) 17 (19.5%) 
No medication 
tried 
61 
(8.4%) 23 (12.8%) 6 (3.5%) 22 (14.8%) 8 (5.8%) 2 (2.3%) 
Drug naïve a 
( 21.7; p=0.0002) 
97 
(12.7%) 37 (19.1%) 14 (7.8%) 29 (18.2%) 11 (7.6%) 6 (6.7%) 
LEDD total b 
( 11.3; p<0.0001) 
284.4 
(212.8) 
229.1 
(191.8) 
314.8 
(186.5) 
236.4 
(214.8) 
357.5 
(251.1) 
310.2 
(185.7) 
LEDD total on 
medicationbc 
( 6.0; p=0.0001) 
328.8 
(194.3) 
287.5 
(171.3) 
341.7 
(168.9) 
295.9 
(200.2) 
387.1 
(238.2) 
336.7 
(168.6) 
aChi-squared test 
b Anova 
cThe LEDD restricted to those who are taking dopaminergic medication  
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FIGURES AND FIGURE LEGENDS 
 
Figure 1. Flow chart of patient entry into study 
 
Figure 2. Within cluster means of the standardised variables for the 5 cluster solution. 
Positive is worse than average and negative better than average. For laterality positive is 
more bilateral than average and negative more unilateral than average. 
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WEB TABLES 
Web Table 1. Detailed description of the variables included in the analysis and  
how they were derived and analysed. 
List of variables named 
 
Explanation 
UPDRS_apathy Categorical from UPDRS part I (question 1.5) 
UPDRS_hallucinations Binary from UPDRS part I (question 1.2) 
UPDRS_speech Categorical UPDRS part III question 3.1 
UPDRS_rigidity Continuous rigidity questions from UPDRS part III (mean score 
3.3) 
UPDRS_bradykinesia Continuous bradykinesia questions from UPDRS part III (mean 
score 3.2,  3.4, 3.5, 3.6, 3.7, 3.8, 3.14) 
UPDRS_postural Continuous postural questions from UPDRS part III (mean score 
3.9, 3.10, 3.11, 3.12, 3.13) 
UPDRS_tremor Continuous tremor questions from UPDRS part III (mean score 
3.15, 3.16, 3.17, 3.18) 
UPDRS_laterality Continuous. Absolute value of right-left questions from UPDRS 
part III  
UPDRS_fatigue Categorical from UPDRS part I (question 1.13) 
UPDRS_pain Categorical from UPDRS part I (question 1.9) 
UPDRS_constipation Categorical from UPDRS part I (question 1.11) 
UPDRS_urinary Categorical from UPDRS part I (question 1.10) 
Sniffin Continuous 
MOCA Continuous – adjusted for education years 
MMSE Continuous 
Phenomic fluency Continuous – age adjusted 
Semantic fluency Continuous – age adjusted 
Purdue total Continuous – Sum from the pegboard test using left hand, right 
hand and both hands 
Purdue assembly Continuous – Total from the assembly part of the purdue 
pegboard test. 
Get go 
 
 
Binary - Dichotomised into top quintile (average time) 
Flamingo Binary (dichotomised into bottom quintile) 
BFI_extraversion Continuous Big Five inventory total 
BFI_agreeableness Continuous Big Five inventory total 
BFI_conscientiousness Continuous Big Five inventory total 
BFI_neuroticism Continuous Big Five inventory total 
BFI_openess Continuous Big Five inventory total 
ESS Continuous Epworth sleepiness scale total 
RBD Continuous  
Honolulu Constipation Categorical- presence of constipation 
Leeds_anxiety Continuous 
Leeds_depression Continuous 
BDI Continuous – Becks Depression Inventory 
QUIP_all Binary – presence of any one of the QUIP scores 
Systolic BP postural drop Continuous - (Mean of lying SBPs) – standing SBP 
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Web Table 2. Statistics to determine the number of clusters from the Ward hierarchical 
clustering.  A higher value of Calinski/Harabasz pseudo-F index indicates more distinct 
clustering and a smaller value of the Duda/Hart pseudo-T squared indicates more distinct 
clustering.  Bold indicates most distinct cluster. 
Number of clusters Calinski/Harabasz 
pseudo-F 
Duda/Hart pseudo T-
squared 
2 98.37 37.46 
3 73.48 41.49 
4 63.46 37.54 
5 57.07 25.17 
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Web Table 3.  Association of clusters with variables not included within the cluster analysis, 
along with a p-value derived from a hypothesis test that the variable is equally distributed 
(i.e. same mean or same proportion) amongst the two clusters.  Note that these variables were 
derived from the complete case and there was some missingness associated with them 
Variable 
(Hypothesis test 
statistic; p-
value) 
Total 
(N=769) 
Cluster 1 
(N=436, 
56.7%) 
Cluster 2 
(N=333, 
43.3%) 
Female a 
(10.4; p=0.0012) 
261 
(33.9%) 
169 
(38.8%) 92 (27.6%) 
Disease duration 
onsetb 
(1.9; p=0.1652) 2.9 (1.9) 2.8 (1.7) 3.0 (2.0) 
Disease duration 
diagnosisb 
(8.5; p=0.0037) 1.3 (1.0) 1.2 (0.9) 1.4 (1.0) 
Age onsetb  
(85.4; p<0.0001) 64.8 (9.7) 62.1 (9.0) 68.3 (9.5) 
Age onset <50 a  
(14.2; p=0.0002) 60 (7.8%) 48 (11.0%) 12 (3.6%) 
UPDRS phenotype a 
(47.7; p<0.0001) 
   Tremor       
dominant 
407 
(53.8%) 
278 
(64.7%) 
129 
(39.6%) 
Indeterminate 95 (12.6%) 45 (10.5%) 50 (15.3%) 
   Postural 
instability gait 
difficulty 
254 
(33.6%) 
107 
(24.9%) 
147 
(45.1%) 
Clinicians global impression of change  a 
(5.7; p=0.1269) 
Much or very 
much improved 
354 
(48.7%) 
194 
(47.7%) 
160 
(50.0%) 
Minimally 
improved 
188 
(25.9%) 
102 
(25.1%) 86 (26.9%) 
No change to 
much worse 
124 
(17.1%) 68 (16.7%) 56 (17.5%) 
No medication 
tried 61 (8.4%) 43 (10.6%) 18 (5.6%) 
Drug naïve a 
(8.2; p=0.0042) 97 (12.7%) 68 (15.7%) 29 (8.7%) 
LEDD total b 
(23.3; p<0.0001) 
284.4 
(212.8) 
252.2 
(209.0) 
326.2 
(210.8) 
LEDD total on 
medicationbc 
(14.4; p=0.0002) 
328.8 
(194.3) 
302.8 
(192.6) 
359.9 
(192.0) 
aChi-squared test 
b Anova 
cThe LEDD restricted to those who are taking dopaminergic medication  
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Web Table 4. Stability of the five cluster solution using our cross-validation approach 
Split dataset Number assigned to the same cluster (%) 
1 644 (83.7%) 
2 556 (72.3%) 
3 510 (66.3%) 
4 496 (64.5%) 
5 631 (82.1%) 
Average 567.4 (73.8%) 
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Web Table 5. Stability of the two cluster solution using our cross-validation approach 
Split dataset Number assigned to the same cluster (%) 
1 742 (96.5%) 
2 713 (92.7%) 
3 758 (98.6%) 
4 754 (98.0%) 
5 744 (96.7%) 
Average 742.2 (96.5%) 
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WEB FIGURE LEGENDS 
Web Figure 1.  Within cluster means of the standardised variables for the 2 cluster solution.  
Positive is worse than average. For laterality positive is more bilateral than average and 
negative more unilateral than average. 
 
Web figure 2.  Pie charts to visually show the association between the UPDRS phenotype 
(popularised by Jankovic et. al) and the 5 cluster solution. 
